CSR Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing novel biologics for cancer and autoimmune diseases.
OncologyImmunology
Technology Platform
Proprietary antibody discovery and protein engineering platform focused on humanization, affinity maturation, and bispecific antibody formatting.
Opportunities
Potential to license lead assets to global pharma for development outside China, providing non-dilutive funding.
Risk Factors
Clinical failure of its lead asset would significantly devalue the company given its concentrated pipeline.
Competitive Landscape
Faces intense competition in the Chinese biologics space from well-funded peers with similar oncology/immunology pipelines and more advanced commercial capabilities.